# A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults

> **NCT07717775** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Gastritis

## Interventions

- **DRUG:** AD-234
- **DRUG:** AD-2341
- **DRUG:** AD-2342

## Key facts

- **NCT ID:** NCT07717775
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717775, "A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07717775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*